Neuropace Inc
NASDAQ:NPCE
Neuropace Inc
NASDAQ:NPCE
Price:
13.64 USD
-1.87%
Market Closed
Updated:
May 5, 2024
Neuropace Inc
Cash from Operating Activities
|
Neuropace Inc
Cash from Operating Activities Peer Comparison
Comparables:
BDX
BSX
SYK
ABT
ISRG
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Neuropace Inc
NASDAQ:NPCE
|
Cash from Operating Activities
-$19.7m
|
CAGR 3-Years
3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash from Operating Activities
$3.4B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Operating Activities
$2.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
40%
|
CAGR 10-Years
8%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash from Operating Activities
$3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
6%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Operating Activities
$7.3B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Operating Activities
$1.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
See Also
What is Neuropace Inc's Cash from Operating Activities?
Cash from Operating Activities
-19.7m
USD
-19.7m
USD
Based on the financial report for Dec 31, 2023, Neuropace Inc's Cash from Operating Activities amounts to -19.7m USD.
What is Neuropace Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
3%
3%
Over the last year, the Cash from Operating Activities growth was 47%. The average annual Cash from Operating Activities growth rates for Neuropace Inc have been 3% over the past three years .
You don't have any saved screeners yet
